Intranasal Delivery of Influenza Subunit Vaccine Formulated with GEM Particles as an Adjuvant
Open Access
- 8 January 2010
- journal article
- Published by Springer Nature in The AAPS Journal
- Vol. 12 (2) , 109-116
Abstract
Nasal administration of influenza vaccine has the potential to facilitate influenza control and prevention. However, when administered intranasally (i.n.), commercially available inactivated vaccines only generate systemic and mucosal immune responses if strong adjuvants are used, which are often associated with safety problems. We describe the successful use of a safe adjuvant Gram-positive enhancer matrix (GEM) particles derived from the food-grade bacterium Lactococcus lactis for i.n. vaccination with subunit influenza vaccine in mice. It is shown that simple admixing of the vaccine with the GEM particles results in a strongly enhanced immune response. Already after one booster, the i.n. delivered GEM subunit vaccine resulted in hemagglutination inhibition titers in serum at a level equal to the conventional intramuscular (i.m.) route. Moreover, i.n. immunization with GEM subunit vaccine elicited superior mucosal and Th1 skewed immune responses compared to those induced by i.m. and i.n. administered subunit vaccine alone. In conclusion, GEM particles act as a potent adjuvant for i.n. influenza immunization.Keywords
This publication has 51 references indexed in Scilit:
- Single dose intranasal immunization with ISCOMATRIX™ vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tractVaccine, 2009
- Towards an oral influenza vaccine: Comparison between intragastric and intracolonic delivery of influenza subunit vaccine in a murine modelVaccine, 2007
- The perfect mix: recent progress in adjuvant researchNature Reviews Microbiology, 2007
- A dose–response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adultsVaccine, 2007
- Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunizationVaccine, 2006
- Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteriaMethods, 2006
- Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccineVaccine, 2004
- Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunityVaccine, 2001
- Th2 Responses to Inactivated Influenza Virus Can Be Converted to Th1 Responses and Facilitate Recovery from Heterosubtypic Virus InfectionThe Journal of Infectious Diseases, 1999
- AGING AND THE MUCOSAL‐ASSOCIATED LYMPHOID SYSTEM*Annals of the New York Academy of Sciences, 1983